Revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Inc (VRTX)
Price$526.66Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B | $4.16B | $3.05B | $2.49B | $1.70B | $1.03B | $580.4M | $1.21B | $1.53B | $1.41B | $143.4M | $101.9M | $175.5M |
| Gross profit | $10.35B | $9.49B | $8.61B | $7.85B | $6.67B | $5.47B | $3.62B | $2.64B | $2.21B | $1.49B | $915.2M | $540.7M | $1.12B | $1.29B | $1.35B | $143.4M | — | — |
| Gross margin | 86.24% | 86.11% | 87.21% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 88.65% | 93.16% | 92.66% | 84.50% | 95.49% | 100.00% | — | — |
| Research & development | $3.91B | $3.63B | $3.16B | $2.54B | $1.94B | $1.64B | $1.75B | $1.42B | $1.32B | $1.05B | $995.9M | $855.5M | $882.1M | $765.9M | $707.7M | $637.4M | $550.3M | $516.9M |
| Operating expenses | $7.83B | $11.25B | $6.04B | $4.62B | $4.79B | $3.35B | $2.97B | $2.41B | $2.37B | $1.69B | $1.50B | $1.27B | $1.82B | $1.48B | $1.30B | $839.4M | $715.9M | $638.2M |
| Operating income | $4.17B | −$232.9M | $3.83B | $4.31B | $2.78B | $2.86B | $1.20B | $635.1M | $123.2M | $9.9M | −$466.9M | −$692.4M | −$610.0M | $46.7M | $113.8M | −$696.1M | −$614.0M | −$462.7M |
| Operating margin | 34.77% | −2.11% | 38.83% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | −45.23% | −119.30% | −50.33% | 3.06% | 8.07% | −485.51% | −602.63% | −263.65% |
| EBITDA | $4.38B | −$25.7M | $4.01B | $4.46B | $2.91B | $2.97B | $1.30B | $707.6M | $184.6M | $71.3M | −$404.5M | −$629.2M | −$561.6M | $84.9M | $148.9M | −$665.6M | −$583.9M | −$430.5M |
| EBITDA margin | 36.52% | −0.23% | 40.66% | 49.89% | 38.39% | 47.79% | 31.33% | 23.22% | 7.42% | 4.19% | −39.19% | −108.40% | −46.34% | 5.56% | 10.55% | −464.27% | −573.08% | −245.30% |
| Net income | $3.95B | −$535.6M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.10B | $263.5M | −$112.1M | −$556.3M | −$738.6M | −$445.0M | −$107.0M | $29.6M | −$754.6M | −$642.2M | −$459.9M |
| Net profit margin | 32.94% | −4.86% | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | −6.58% | −53.89% | −127.25% | −36.72% | −7.01% | 2.10% | −526.35% | −630.27% | −262.02% |
| Basic EPSper basic share | $15.46 | -$2.08 | $14.05 | $12.97 | $9.09 | $10.44 | $4.58 | $8.24 | $1.06 | -$0.46 | -$2.31 | -$3.14 | -$1.98 | -$0.50 | $0.14 | -$3.77 | -$3.71 | -$3.27 |
| Diluted EPSper diluted share | $15.32 | -$2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | -$0.46 | -$2.31 | -$3.14 | -$1.98 | -$0.50 | $0.14 | -$3.77 | -$3.71 | -$3.27 |
Owners
Reported shareholders
10.31%of listed shares
Capital World Investors26.12M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Capital World Investors | 10.31%26.12M shares |
BlackRock, Inc. | 9.52%24.11M shares |
Capital Research Global Investors | 7.69%19.49M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.54%16.58M shares |
STATE STREET CORP | 4.69%11.87M shares |
Invesco Ltd. | 3.17%8.04M shares |
JPMORGAN CHASE & CO | 2.57%6.52M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.38%6.02M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.93%4.88M shares |
Capital International Investors | 1.85%4.7M shares |
LOOMIS SAYLES & CO L P | 1.55%3.92M shares |
FRANKLIN RESOURCES INC | 1.32%3.35M shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.28%3.25M shares |
MORGAN STANLEY | 1.28%3.24M shares |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.22%3.09M shares |
BANK OF AMERICA CORP /DE/ | 1.20%3.04M shares |
ALLIANCEBERNSTEIN L.P. | 1.19%3.02M shares |
JENNISON ASSOCIATES LLC | 1.18%3M shares |
NORGES BANK | 1.17%2.97M shares |
AMERIPRISE FINANCIAL INC | 1.03%2.6M shares |
Percentages use 253.35M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 · 10b5-1 | Bozic CarmenEVP and CMO | SellCommon Stock | 596 | $482.50 | $287.6K | 15.3K |
| Jun 18, 2026Form 4 · 10b5-1 | Bozic CarmenEVP and CMO | SellCommon Stock | 1.0K | $462.17 | $471.4K | 15.9K |
| Jun 15, 2026Form 4 · 10b5-1 | Bozic CarmenEVP and CMO | SellCommon Stock | 4.1K | $450.00 | $1.83M | 17.0K |
| Jun 5, 2026Form 4 · 10b5-1 | Bozic CarmenEVP and CMO | SellCommon Stock | 1.7K | $450.00 | $785.3K | 21.0K |
| Jun 1, 2026Form 4 · 10b5-1 | Liu JoyEVP and Chief Legal Officer | SellCommon Stock | 828 | $439.91 | $364.2K | 20.0K |